- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NIH to offer radiology CRADAs
The radiology department of the National Institutes of Health Clinical Center is seeking Cooperative Research and Development Agreements (CRADAs) with one or more medical equipment manufacturers. The CRADAs, which enable the NIHCC and companies to
The radiology department of the National Institutes of Health Clinical Center is seeking Cooperative Research and Development Agreements (CRADAs) with one or more medical equipment manufacturers. The CRADAs, which enable the NIHCC and companies to collaborate on research projects, cover MRI, MR spectroscopy, molecular imaging, image processing, and image-guided surgery.
The objective of the project is the rapid publication of research findings and the timely commercialization of improved diagnostic and treatment strategies. Particular emphasis is placed on discoveries that enhance clinical research, according to the NIHCC. While the NIHCC does not contribute funding, the center can offer collaborators access to facilities, staff, materials, and expertise.
Collaborators can also elect an option to be an exclusive or nonexclusive licensee to government intellectual property rights arising under the CRADA and may qualify as a co-inventor of new technology that is developed under the agreement. For more information, contact Steve Galen at 301/594-4509. Statements of interest must be received by Dec. 10, with formal proposals due 30 days later.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
